

Deal Corner

August 12, 2021

W HEALTH LEADS INVESTMENT INTO BEATO

DEAL BRIEF

W Health Global Series LLC (“W Health Ventures”), along with other investors, led the Pre-Series B investment round of approx. USD 5.7 million in Health Arx Technologies Private Limited (undertaking business as Beato). Beato offers services to patients with diabetes through a smartphone glucometer and mobile application, which connects them with in-house specialists, shares and analyses readings, tracks fitness levels, and manages the diet of the patient with a range of diabetic-friendly food products. W Health Ventures is a Boston-based venture capital firm focused on helping entrepreneurs build the future of healthcare.

OUR ROLE

We, at Nishith Desai Associates, acted as the India legal counsel to W Health Ventures. We advised them on the legal, tax and regulatory aspects of the transaction.

NEWS AND MEDIA REPORTS RELATED TO THE DEAL

<https://www.vccircle.com/w-health-ventures-pharmeasy-others-invest-in-diabetes-management-app-beato/>

<https://www.cnbctv18.com/startup/beato-raises-rs-42-crore-in-funding-led-by-w-health-ventures-9910141.htm>

<https://inc42.com/buzz/beato-raises-inr-42-cr-funding-from-w-health-ventures-pharmeasy/>

<https://www.healthcareradius.in/features/business/30081-beato-raises-rs-42-crore-in-funding-led-by-w-health-ventures>

DISCLAIMER

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

Research Papers

Fintech

May 05, 2025

Medical Device Industry in India

April 28, 2025

Clinical Trials and Biomedical Research in India

April 22, 2025

Research Articles

2025 Watchlist: Life Sciences Sector India

April 04, 2025

Re-Evaluating Press Note 3 Of 2020: Should India's Land Borders Still Define Foreign Investment Boundaries?

February 04, 2025

INDIA 2025: The Emerging Powerhouse for Private Equity and M&A Deals

January 15, 2025

Audio

CCI's Deal Value Test

February 22, 2025

Securities Market Regulator's Continued Quest Against “Unfiltered” Financial Advice

December 18, 2024

Digital Lending - Part 1 - What's New with NBFC P2Ps

November 19, 2024

NDA Connect

Connect with us at events, conferences and seminars.

NDA Hotline

Click here to view Hotline archives.

Video

Vyapak Desai speaking on the danger of deepfakes | Legally Speaking with Tarun Nangia | NewsX

April 01, 2025

**SIAC 2025 Rules: Key changes &
Implications**

February 18, 2025
